Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells

Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC patients indicate that sorafenib alone has only moderate antitumor efficacy, and could not inhibit disease metastasis and progressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jianhua, Liu, Yahui, Meng, Lingyu, Ji, Bai, Yang, Daqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479120/
https://www.ncbi.nlm.nih.gov/pubmed/28638267
http://dx.doi.org/10.7150/ijms.19033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479120/
https://www.ncbi.nlm.nih.gov/pubmed/28638267
http://dx.doi.org/10.7150/ijms.19033

Ejemplares similares